MRI features predict survival and molecular markers in diffuse lower-grade gliomas

Neuro Oncol. 2017 Jun 1;19(6):862-870. doi: 10.1093/neuonc/now256.


Background: Previous studies have shown that MR imaging features can be used to predict survival and molecular profile of glioblastoma. However, no study of a similar type has been performed on lower-grade gliomas (LGGs).

Methods: Presurgical MRIs of 165 patients with diffuse low- and intermediate-grade gliomas (histological grades II and III) were scored according to the Visually Accessible Rembrandt Images (VASARI) annotations. Radiomic models using automated texture analysis and VASARI features were built to predict isocitrate dehydrogenase 1 (IDH1) mutation, 1p/19q codeletion status, histological grade, and tumor progression.

Results: Interrater analysis showed significant agreement in all imaging features scored (k = 0.703-1.000). On multivariate Cox regression analysis, no enhancement and a smooth non-enhancing margin were associated with longer progression-free survival (PFS), while a smooth non-enhancing margin was associated with longer overall survival (OS) after taking into account age, grade, tumor location, histology, extent of resection, and IDH1 1p/19q subtype. Using logistic regression and bootstrap testing evaluations, texture models were found to possess higher prediction potential for IDH1 mutation, 1p/19q codeletion status, histological grade, and progression of LGGs than VASARI features, with areas under the receiver-operating characteristic curves of 0.86 ± 0.01, 0.96 ± 0.01, 0.86 ± 0.01, and 0.80 ± 0.01, respectively.

Conclusion: No enhancement and a smooth non-enhancing margin on MRI were predictive of longer PFS, while a smooth non-enhancing margin was a significant predictor of longer OS in LGGs. Textural analyses of MR imaging data predicted IDH1 mutation, 1p/19q codeletion, histological grade, and tumor progression with high accuracy.

Keywords: 1p/19q codeletion; IDH1 mutation; MR imaging; lower-grade gliomas; texture analysis.

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Brain Neoplasms / genetics
  • Brain Neoplasms / mortality*
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 1
  • Chromosomes, Human, Pair 19
  • Combined Modality Therapy
  • Disease Progression
  • Follow-Up Studies
  • Glioma / genetics
  • Glioma / mortality*
  • Glioma / pathology
  • Glioma / therapy
  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Magnetic Resonance Imaging / methods*
  • Mutation*
  • Neoplasm Grading
  • Survival Rate


  • Biomarkers, Tumor
  • Isocitrate Dehydrogenase